CAMBRIDGE, Mass., Oct. 17 /PRNewswire-FirstCall/ -- Xanthus Life Sciences,
Inc., a privately-held oncology drug development company, today announced that
Richard T. Dean, Ph.D., President and CEO of Xanthus, will present a company
overview and update on the Company's oncology pipeline at the 2005 BIO
InvestorForum conference on Thursday, October 20th at 2:00 pm at The Palace
Hotel in San Francisco. A live audio webcast of the presentation will be
available on the Company's website located at http://www.xanthus.com. A replay
of the presentation will be posted on the Xanthus website approximately thirty
minutes after the event.
About Xanthus
Xanthus is an oncology drug development company with three small molecule
candidates advancing in clinical and preclinical development for multiple
cancer indications. Each of these product candidates (Xanafide(TM),
Symadex(TM) and Clomet(TM) ) was in-licensed based on significant clinical
and/or preclinical data supporting safety and activity.
Xanthus is headquartered in Cambridge, Massachusetts with an additional
facility in Montreal, Quebec. More information is available at
http://www.xanthus.com.
Contacts:
Kari Watson, MacDougall Biomedical Communications, Inc. --
kwatson@macbiocom.com or (508) 647-0209
John A. McCarthy, Jr., SVP & CFO, Xanthus Life Sciences, Inc. --
john.mccarthy@xanthus.com or (617) 225-0522, ext. 125
SOURCE Xanthus Life Sciences, Inc.
 back to top
Related links:
http://www.xanthus.com
CONTACT:
Kari Watson of MacDougall Biomedical
Communications, Inc., +1-508-647-0209, kwatson@macbiocom.com; or
John A. McCarthy, Jr., SVP & CFO of Xanthus Life Sciences, Inc.,
+1-617-225-0522, ext. 125, john.mccarthy@xanthus.com
|
